ViaDerma Inc (VDRM)

[Fdc4]

I have explained such before several times. Please seek old post. 2nd, explain to me why in hell will OTIKO spend money on a petty PR on the following below when he could wait and present all together with FDA submission?

1) Insurance inclusion.
2) Long term stability test completion.
3) Update on new manufacturer.
4) Update on Ultra sales in US and other countries.
5) New sales channels and large contracts for Ultra.

You have to learn to read CEO you are dealing with. OTIKO doesn’t like to spend money on PRs, specially when it is not necessary. Last time he explained he is aiming for OTCQB (This is why he isn’t doing Yield sign update), for this to happen he must get good results on FDA in order to keep moving forward with agenda. I bet you are going to be the first one to criticize him if he makes PR without FDA update. NOTE: do your DD, when FDA ask for more data, is because the sender didn’t provide what was needed or made mistake on first submission. Everything gets reset back to 90 days again. I have seen this happened in other biopharma companies.

NOTE: All your concern can also be explained in the next fillings, not need to spend AGAIN money on a PR. Catch my point mate?